Jose Olague
Chief Tech/Sci/R&D Officer bei ALPHA TEKNOVA, INC.
Profil
Jose Olague is currently the Vice President-Engineering at Alpha Teknova, Inc. He previously worked as the Director-Manufacturing Engineering & Maintenance at Intarcia Therapeutics, Inc. and as the Director-Manufacturing & Engineering at Avinger, Inc. He obtained an undergraduate degree from Instituto Tecnológico de Ciudad Juárez.
Aktive Positionen von Jose Olague
| Unternehmen | Position | Beginn |
|---|---|---|
| ALPHA TEKNOVA, INC. | Chief Tech/Sci/R&D Officer | 01.05.2020 |
Ehemalige bekannte Positionen von Jose Olague
| Unternehmen | Position | Ende |
|---|---|---|
| AVINGER, INC. | Corporate Officer/Principal | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Ausbildung von Jose Olague
| Instituto Tecnológico de Ciudad Juárez | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ALPHA TEKNOVA, INC. | Health Technology |
| AVINGER, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
